<DOC>
	<DOCNO>NCT02732314</DOCNO>
	<brief_summary>This 13 week randomize , double blind , parallel group , home use study among approximately 60 male female subject , age 12 65 year old inclusive , atopic dermatitis ( AD ) SCORAD &gt; 16 . Treatment group assignment balance disease severity , age , body location AD lesion . The study consist 1 week washout phase 12 week treatment phase . During washout phase , subject provide bar soap bath shower must refrain use product body ( exclude face ) include topical corticosteroid , ointment , lotion , sunscreen , etc . During treatment phase , subject randomize 1 4 test leg . Throughout treatment phase , subject require use provide bar soap bath shower apply test product twice per day , morning evening . No additional cream , moisturizers , lotion cleanser provide permitted duration study . Normal facial hair care product permit , however , must contain anti-bacterial ingredient ( e.g . antidandruff shampoo , acne product , etc ) . SCORAD , EASI PGA incorporate whole body assessment . However , Baseline visit , subject active inflammatory lesion site adjacent non-lesion , non-inflammatory site identify marked instrumental biopsy evaluation Baseline subsequent visit . Instrumental evaluation , imaging , expert visual grade self-assessments perform throughout study . Tolerability evaluate incidence AE 's ( define per CTCAE ) , exacerbation AD lesion , application site reactions/infections , lab evaluation throughout study . There additional consumption compliance check well dermatologic evaluation ensure subject 's condition become extensively bad visit . A subset subject 2mm punch biopsy collect designated lesion non-lesion sit 3 time point throughout study . The subset subject determine subject willingness participate biopsy portion well dermatologic evaluation determination biopsy candidacy .</brief_summary>
	<brief_title>Efficacy Tolerability New Topical Formulations Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Desonide</mesh_term>
	<criteria>Is generally healthy , male female , 1265 year old , inclusive Diagnosis moderate great Atopic Dermatitis determine Physician 's Global Assessment ( PGA 3 4 ) Is currently participate participate another interventional clinical study facility past 2 week Currently diagnose treat cancer past 5 year . Requires topical systemic medication could affect course atopic dermatitis study period ( except inhale steroid and/or stable antihistamine asthma allergy ) . Has know hypersensitivity corticosteroid cream . Has know sensitivity Epinephrine , Xylocaine topical antibiotic . Has wound heal bloodclotting abnormality . Has active infection use antibiotic past 7 day . Has physical attribute skin condition might interfere clear visual instrumental assessments. ( i.e . cut , sunburn , birth mark , tattoo , extensive scarring , excessive hair growth acne ) Has immunologic infectious disease ( e.g . hepatitis , tuberculosis , HIV AIDS , lupus rheumatoid arthritis ) could place subject risk interfere accuracy study result . Has use immunosuppressant drug immunotherapy within past 30 day 5 halflives . Is employee Sponsor Company clinical test site . Is diabetic . Is dependent oral medication skin disease/condition could , opinion Investigator tolerate restriction discontinue medicine require study . Is currently pregnant lactate plan become pregnant next 6 month . Has history keloid formation follow skin injury . Is routinely take anticoagulant medication ( i.e . Plavix , Coumadin , warfarin , heparin , etc . ) Any condition factor Investigator duly assign representative believe may affect ability subject complete study interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>